文献速递淋巴瘤造血干细胞移植与细胞治疗

评估高风险复发或难治性非霍奇金淋巴瘤患者接受高剂量放射性碘标记托西莫单抗(抗CD20抗体)、依托泊苷和环磷酰胺序贯自体移植疗效的II期试验

A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.
PubMed 文献 · Am J Hematol · 2020-04-22

这项II期试验评估了高风险复发或难治性B细胞非霍奇金淋巴瘤患者在接受自体干细胞移植前使用高剂量放射性免疫治疗联合依托泊苷和环磷酰胺的方案。107例患者中,侵袭性淋巴瘤、惰性淋巴瘤和套细胞淋巴瘤的10年无进展生存率分别为62%、64%和43%,10年总生存率分别为61%、71%和48%。方案可行性好,安全性与标准预处理方案相似,100天非复发死亡率为2.8%,晚期髓系恶性肿瘤发生率为6%。

要点

  • 高剂量I-131托西莫单抗联合依托泊苷、环磷酰胺序贯自体移植在高风险复发或难治性B细胞非霍奇金淋巴瘤中可行、安全且有效。
  • 中位随访10.1年,侵袭性、惰性和套细胞淋巴瘤的10年无进展生存率分别为62%、64%和43%。
  • 100天非复发死亡率为2.8%,晚期髓系恶性肿瘤发生率为6%。

核心结论

  • 高剂量I-131托西莫单抗、依托泊苷和环磷酰胺序贯自体干细胞移植在高风险复发或难治性非霍奇金淋巴瘤中显得可行、安全且有效,10年无进展生存率估计为43%-64%。
  • 鉴于复发或难治性非霍奇金淋巴瘤的新型细胞疗法,含高剂量放射性免疫治疗的方案具有可比的疗效和安全性,可进行前瞻性比较。

研究设计与样本

  • 这是一项II期试验,评估高风险复发或难治性B细胞非霍奇金淋巴瘤患者在接受自体干细胞移植前使用高剂量放射性免疫治疗和化疗。
  • 入组标准为年龄小于60岁、CD20阳性的复发或难治性非霍奇金淋巴瘤患者;套细胞淋巴瘤患者可在首次缓解期进行移植。
  • 共治疗107例患者,包括侵袭性淋巴瘤29例、惰性淋巴瘤45例和套细胞淋巴瘤33例。
  • 患者接受I-131托西莫单抗,关键正常器官剂量≤25Gy,随后接受依托泊苷、环磷酰胺和自体干细胞移植。
  • 主要终点为无进展生存期,次要终点为总生存期、毒性和耐受性。

主要发现

  • 中位随访10.1年,侵袭性淋巴瘤、惰性淋巴瘤和套细胞淋巴瘤组的10年无进展生存率分别为62%、64%和43%。
  • 侵袭性淋巴瘤、惰性淋巴瘤和套细胞淋巴瘤组的10年总生存率分别为61%、71%和48%。
  • 毒性反应与标准预处理方案相似,100天非复发死亡率为2.8%。
  • 6%的患者出现晚期髓系恶性肿瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiation is the most effective treatment for localized lymphoma, but treatment of multifocal disease is limited by toxicity. Radioimmunotherapy (RIT) delivers tumoricidal radiation to multifocal sites, further augmenting response by dose-escalation. This phase II trial evaluated high-dose RIT and chemotherapy prior to autologous stem-cell transplant (ASCT) for high-risk, relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). The primary endpoint was progression free survival (PFS). Secondary endpoints were overall survival (OS), toxicity, and tolerability. Patients age < 60 years with R/R NHL expressing CD20 were eligible. Mantle cell lymphoma (MCL) patients could proceed to transplant in first remission. Patients received I-131-tositumomab delivered at ≤25Gy to critical normal organs, followed by etoposide, cyclophosphamide and ASCT. A group of 107 patients were treated including aggressive lymphoma (N = 29), indolent lymphoma (N = 45), and MCL (N = 33). After a median follow-up of 10.1 years, the 10-year PFS for the aggressive, indolent, and MCL groups were 62%, 64%, 43% respectively. The 10-year OS for the aggressive, indolent, and MCL groups were 61%, 71%, 48% respectively. Toxicities were similar to standard conditioning regimens and non-relapse mortality at 100 days was 2.8%. Late myeloid malignancies were seen in 6% of patients. High-dose I-131-tositumomab, etoposide and cyclophosphamide followed by ASCT appeared feasible, safe, and effective in treating NHL, with estimated PFS at 10-years of 43%-64%. In light of novel cellular therapies for R/R NHL, high-dose RIT-containing regimens yield comparable efficacy and safety and could be prospectively compared.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Chow VA, Rajendran JG, Fisher DR, et al. A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma. Am J Hematol. 2020. PMID: 32243637. doi:10.1002/ajh.25818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。